Načítá se...
Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
Adeno-associated virus (AAV) vector-based gene therapy is currently the only in vivo gene therapy approved in the US and Europe. The recent tragic death of three children in a clinical trial to treat X-Linked Myotubular Myopathy by delivering myotubularin with an AAV8 vector notwithstanding, AAV rem...
Uloženo v:
| Vydáno v: | Front Immunol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8010240/ https://ncbi.nlm.nih.gov/pubmed/33815421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.658399 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|